Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Chemo nausea still a problem despite standard care, study finds

NCT ID NCT01440465

Knowledge-focused Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracked 300 cancer patients receiving their first round of chemotherapy to see how often nausea and vomiting still happen, even with standard anti-nausea medicines. Participants filled out questionnaires about their symptoms in the first 24 hours and up to 4 days after treatment. The goal was to better understand what factors lead to these side effects, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

300 people

The number who actually took part.

Start date

Jul 2011

Finished

Feb 2013

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients treated with first line chemotherapy with intravenous (IV) to solid tumors or hematologic.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged over 18 years * With solid tumors or hematologic in first line chemotherapy, administered intravenously, * Able to understand the meaning of the questions * Having given their written consent to participate in the survey. Exclusion Criteria: This does not concern patients who: * Do not give their consent for participation * Do not speak French * Suffer from cognitive deficits * Are under therapy * Must receive a combination of radio-chemotherapy * Present an occlusive syndrome * Metastases (s) brain (s) clinically symptomatic (s) or radiologically proven (s) or a (of) tumor (s) brain (s) * Have been previously treated with chemotherapy * Present a cons-indication to corticosteroids, with anti-serotonin or NK1 receptor inhibitors * Pregnant or breastfeeding.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer hematopoietic and lymphoid cell neoplasm Nausea neoplasm Vomiting

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer Nausea Vomiting

Contacts and locations

Locations

  • Centre François Baclesse

    Caen, 14076, France

  • Centre Jacques Monod

    Flers, 61104, France

  • Centre Maurice Tubiana

    Caen, 14052, France

  • Centre de la Baie

    Avranches, 50307, France

  • Centre hospitalier

    Bayeux, 14400, France

  • Centre hospitalier public du cotentin

    Cherbourg-Octeville, 50100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.